AstraZeneca Divests Angina Drug to China Medical System Holdings

AstraZeneca has completed the divestment of the global rights to Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement, AstraZeneca will receive $190 million for the rights to Imdur.

Imdur is a mature medicine for the prevention of angina in patients with heart disease and achieved global sales outside the US of $57 million in 2015.

Source: AstraZeneca

Leave a Reply

Your email address will not be published. Required fields are marked *